Evidence map›Paper›PMID 40996315›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025

SMAGS-LASSO: A Novel Feature Selection Method for Sensitivity Maximization in Early Cancer Detection.

Hamid Khoshfekr Rudsari, Sara Khorami-Sarvestani, Johannes F Fahrmann, James P Long, Samir Hanash, Kim-Anh Do, Ehsan Irajizad

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hamid Khoshfekr RudsariDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-7856-0038
Sara Khorami-SarvestaniDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-0534-5345
Johannes F FahrmannDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5088-0198
James P LongDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5853-5938
Samir HanashDepartment of Clinical Cancer Prevention, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-4210-1593
Kim-Anh DoDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8710-7131
Ehsan IrajizadDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-7510-4849

Funding

Targeting Tumor Microenvironment-Induced Therapy Resistance in Prostate Cancer Bone MetastasisP50CA140388 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI THOMPSON, TIMOTHY CHARLES · 2009 to 2022
$23.4M
Center for Clinical and Translational Sciences (CCTS)UL1TR000371 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2012 to 2016
$13.4M
Clinical Validation Center for Lung Cancer Early DetectionU01CA271888 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HANASH, SAMIR M · 2022 to 2025
$4.9M
Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston (CCTS, UTHealth) TR000371Lyda Hill Philanthropies (LH)National Cancer Institute (NCI) P50CA140388National Institutes of Health (NIH) RP160693National Institutes of Health (NIH) U01CA271888NCATS NIH HHS UL1 TR000371NCI NIH HHS P50 CA140388NCI NIH HHS U01 CA271888University of Texas MD Anderson Cancer Center (MD Anderson)
6 · The paper itself

Abstract

backgroundSensitivity and specificity are foundational metrics for cancer detection tools. However, most machine learning algorithms prioritize overall accuracy during optimization, which fails to align with clinical priorities of early detection. We aim to develop a feature selection machine learning algorithm while maximizing sensitivity at a given specificity.

methodsWe developed SMAGS-LASSO, a machine learning algorithm that combines our developed Sensitivity Maximization at a Given Specificity (SMAGS) framework with L1 regularization for feature selection. This approach simultaneously optimizes sensitivity at user-defined specificity thresholds while performing feature selection. SMAGS-LASSO utilizes a custom loss function with L1 regularization and multiple parallel optimization techniques. We used train-test splits and cross-validation, comparing against LASSO and random forest using sensitivity and AUC metrics. We evaluated our method on synthetic datasets and real-world protein colorectal cancer biomarker data.

resultsIn synthetic datasets designed to contain strong signals for both sensitivity and specificity, SMAGS-LASSO significantly outperformed standard LASSO, achieving sensitivity of 1.00 (95% confidence interval, 0.98-1.00) compared with 0.19 (95% confidence interval, 0.13-0.23) for LASSO at 99.9% specificity. In colorectal cancer data, SMAGS-LASSO demonstrated 21.8% improvement over LASSO (P value = 2.24E-04) and 38.5% over random forest (P value = 4.62E-08) at 98.5% specificity while selecting the same number of biomarkers.

conclusionsSMAGS-LASSO enables the development of minimal biomarker panels that maintain high sensitivity at predefined specificity thresholds, offering superior performance for early cancer detection. IMPACT: This method provides a promising approach for early cancer detection and other medical diagnostics requiring sensitivity-specificity optimization.

Indexed as

Colorectal NeoplasmsEarly Detection of CancerMachine LearningAlgorithmsBiomarkers, TumorHumansSensitivity and SpecificityBiomarkers, Tumor

Identifiers

PMID40996315
PMCPMC12570486

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.